Sensei Biotherapeutics Inc (HAM:407)

€ 0.554 0.012 (2.21%) Market Cap: 15.15 Mil Enterprise Value: -33.83 Mil PE Ratio: 0 PB Ratio: 0.28 GF Score: 36/100

Sensei Biotherapeutics Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Sensei Biotherapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Sensei Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Sensei Biotherapeutics Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 23, 2023
Sensei Biotherapeutics Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Sensei Biotherapeutics Inc at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Sensei Biotherapeutics Inc Virtual VISTA Science Symposium Transcript
Nov 16, 2021
Sensei Biotherapeutics Inc to Discuss Prioritization of SNS-401-NG and SNS-VISTA Call Transcript
Jun 28, 2021

Sensei Biotherapeutics Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 23, 2023 / 04:00PM GMT

Release Date Price: €1.36 (+2.95%)

Transcript

Sam Semenkow

Citigroup Inc. - Analyst

Good morning, everyone, and welcome to this session of Citi's Virtual Oncology Leadership Summit. I am Sam Semenkow, one of the biotech analysts here at Citi.

And today, it's my pleasure to host Sensei Biotherapeutics. I'd like to welcome John Celebi, President and Chief Executive Officer at Sensei and Edward van der Horst, Chief Scientific Officer at Sensei. John and Edward, thank you for being here.

John Celebi

Sensei Biotherapeutics, Inc. - President & CEO

Thank you, Sam. Thanks for hosting us.

Edward van der Horst

Sensei Biotherapeutics, Inc. - Chief Scientific Officer

Thank you.

Sam Semenkow

Citigroup Inc. - Analyst

Yeah, so just a note to those listening live, if you have any questions for John and Edward during the session, please send them to my e-mail at [email protected], and I'll be happy to ask them on your behalf. So with that, John, if you could start us off with just a brief overview of the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.